Evogene (NYSE: EVGN) reported Q4 EPS of ($0.22), $0.05 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.46 million versus the consensus estimate of $3.9 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.